Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Human Cancer Immunology and Cancer Vaccine Development

Development of cancer vaccines with the MAGE-3 protein

Vincent Brichard
Vincent Brichard
GSK Biologicals, Rixensart, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 2005
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

GSK Biologicals’ approach is based upon immunizing cancer patients with a vaccine composed of a recombinant MAGE-3-derived protein combined with an immunological adjuvant. Phase I/II clinical trials have been, and are being, performed in various indications, with emphasis upon cutaneous metastatic melanoma and NSCLC. Trials have been conducted to optimize the immune response to the MAGE-3 antigen, as follows:

  • (a) In a study evaluating the recombinant MAGE-3 protein alone (administered i.d. and s.c. without immunological adjuvant), a few patients responded to the treatment.

  • (b) Another study employed MAGE-3 combined with the GSK proprietary adjuvant AS02B. This was administered to 49 metastatic melanoma patients. Some responses among patients without visceral disease were observed and will be detailed; no patient with visceral disease responded to treatment. This accords with other observations that active immunotherapy is more effective in early-stage patients. In the same study, a bladder-cancer patient showed partial response.

  • (c) The MAGE-3 protein, either in solution combined with AS02B or pulsed onto dendritic cells, was administered to 19 patients.

  • (d) The MAGE-3 protein was administered in combination with the immunostimulatory oligodeoxyribonucleotide CpG 7909 to a total of 16 patients in two different dosages.

  • (e) A new adjuvant (AS15) containing CpG 7909 has been developed and tested in pre-clinical studies, in which it was found to stimulate mostly type 1 T-cell response, achieving a more robust CD8 response and better immunoprotection in a tumor challenge model. This adjuvant is now being tested in a randomized Phase II study conducted in collaboration with the EORTC melanoma group (MAGE-3 protein with AS02B or AS15; stage III/IVa early metastatic cutaneous melanoma without visceral disease). The trial design includes in particular an objective assessment of response based upon criteria adapted from the RECIST criteria for assessing solid tumors. The modified RECIST criteria are applicable to lesions below 2 mm in size and to skin lesions. Because response to active immunotherapy is slow, and because patients with mixed response have been found to proceed to complete or partial response after several series of vaccinations, this study is designed to identify patients who respond after long-term vaccinations.

Following early results of the above studies, a placebo-controlled, randomized double-blind study of the MAGE-3 antigen plus AS02B in NSCLC was initiated. The planned 182 patients have been recruited; initial data suggest that the treatment is being well tolerated.

Altogether, these results show that the MAGE-3 protein antigen combined with an immunological adjuvant is active in metastatic melanoma. Current trials are aimed at evaluating the efficacy of this treatment in order to achieve development of an effective vaccine.

Major collaborators in the studies described above have been: The EORTC Melanoma Group (Brussels); Prof. Wim Kruit (Erasmus MC, Rotterdam); Profs. Thierry Boon and Marie Marchand (Ludwig Institute for Cancer Research, Brussels); Prof. Thierry Velu (Hôpital Erasme, Brussels).

This abstract was published in Cancer Immunity, a Cancer Research Institute journal that ceased publication in 2013 and is now provided online in association with Cancer Immunology Research.

  • Copyright © 2005 by Vincent Brichard
PreviousNext
Back to top
Cancer Immunity Archive: 5 (Suppl 1)
January 2005
Volume 5, Issue Suppl 1
  • Table of Contents

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Development of cancer vaccines with the MAGE-3 protein
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Development of cancer vaccines with the MAGE-3 protein
Vincent Brichard
Cancer Immun January 1 2005 (5) (Suppl 1) 16;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Development of cancer vaccines with the MAGE-3 protein
Vincent Brichard
Cancer Immun January 1 2005 (5) (Suppl 1) 16;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Vaccine strategies against NY-ESO-1 in cancer patients
  • Tumor-specific T cells induced in melanoma patients either naturally or by vaccination with peptides, IFA ± CpG oligodeoxynucleotides
  • NY-ESO-1 protein-based cancer vaccines: the Melbourne experience
Show more Human Cancer Immunology and Cancer Vaccine Development
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement